|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4889818A
(en)
|
1986-08-22 |
1989-12-26 |
Cetus Corporation |
Purified thermostable enzyme
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
US6632670B1
(en)
|
1995-09-08 |
2003-10-14 |
Genzyme Corporation |
AAV vectors for gene therapy
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
EP1012236A1
(en)
|
1997-08-15 |
2000-06-28 |
Rubicon Laboratory Inc. |
Retrovirus and viral vectors
|
|
EP1015619A1
(en)
|
1997-09-19 |
2000-07-05 |
The Trustees Of The University Of Pennsylvania |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
JP2002504357A
(ja)
|
1998-02-27 |
2002-02-12 |
ザ・ジェネラル・ホスピタル・コーポレイション |
Ｈｅｌｉｏｓ遺伝子
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
AU780231B2
(en)
|
1998-11-10 |
2005-03-10 |
University Of North Carolina At Chapel Hill, The |
Virus vectors and methods of making and administering the same
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
US6168991B1
(en)
|
1999-06-25 |
2001-01-02 |
Lucent Technologies Inc. |
DRAM capacitor including Cu plug and Ta barrier and method of forming
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
AU2584901A
(en)
|
1999-12-22 |
2001-07-03 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
|
|
GB2375113B
(en)
|
2000-01-21 |
2004-10-20 |
Biovex Ltd |
A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
HUP0400882A3
(en)
|
2001-05-11 |
2011-01-28 |
Wellstat Biologics Corp |
Oncolytic virus therapy
|
|
CA2452517A1
(en)
|
2001-07-11 |
2003-01-23 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
|
AU2003258060B2
(en)
|
2002-03-27 |
2007-07-12 |
Baylor College Of Medicine |
Potent oncolytic herpes simplex virus for cancer therapy
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
US20050220818A1
(en)
|
2002-06-21 |
2005-10-06 |
Wellstat Biologics Corporation |
Administration of therapeutic viruses
|
|
AU2003268505A1
(en)
|
2002-09-09 |
2004-03-29 |
University Of Tennessee Research Foundation |
Recombinatant mutants of rhabdovirus and methods of use thereof
|
|
JP2007524363A
(ja)
|
2003-03-27 |
2007-08-30 |
オタワ ヘルス リサーチ インスティチュート |
変異体水疱性口内炎ウイルスおよびそれらの使用
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
ATE420160T1
(de)
|
2003-06-18 |
2009-01-15 |
Genelux Corp |
Modifizierte rekombinante vacciniaviren, verwendungen davon
|
|
EP2345731B1
(en)
|
2003-09-30 |
2015-10-21 |
The Trustees of the University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
|
US20070003520A1
(en)
|
2003-11-17 |
2007-01-04 |
Brown Susanne M |
Mutant viruses
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
AU2005277831B2
(en)
|
2004-07-10 |
2012-11-22 |
The Institute For Cancer Research |
Genetically modified human natural killer cell lines
|
|
US20090208924A1
(en)
|
2004-12-01 |
2009-08-20 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of Replication Competent Viruses for Therapeutic Use
|
|
EP1885186B1
(en)
|
2005-06-01 |
2015-09-02 |
California Institute Of Technology |
Method of targeted gene delivery using viral vectors
|
|
AU2006262021C1
(en)
|
2005-06-23 |
2012-05-10 |
The University Of Houston |
Use of mutant Herpes Simplex Virus-2 for cancer therapy
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
EP2097517B1
(en)
|
2006-10-16 |
2014-06-04 |
Genelux Corporation |
Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
|
|
US20100178684A1
(en)
|
2006-12-21 |
2010-07-15 |
Woo Savio L C |
Transgenic oncolytic viruses and uses thereof
|
|
GB2446721B
(en)
|
2007-02-16 |
2009-03-25 |
Crusade Lab Ltd |
Herpes simplex viruses and methods of viral replication
|
|
DE602008003684D1
(de)
|
2007-04-26 |
2011-01-05 |
Sangamo Biosciences Inc |
Gezielte integration in die ppp1r12c-position
|
|
CA2690627C
(en)
|
2007-06-15 |
2014-12-02 |
Genelux Corporation |
Microorganisms for imaging and/or treatment of tumors
|
|
JP2010533718A
(ja)
|
2007-07-18 |
2010-10-28 |
ジェネラックス・コーポレイション |
腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
|
|
JP5282040B2
(ja)
|
2007-09-28 |
2013-09-04 |
オリンパス株式会社 |
Ｆｃ受容体遺伝子導入ＮＫ細胞を用いた抗体依存性細胞傷害のアッセイ方法
|
|
WO2009054996A2
(en)
|
2007-10-25 |
2009-04-30 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
US20120052003A9
(en)
|
2008-05-16 |
2012-03-01 |
Szalay Aladar A |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
KR101133185B1
(ko)
|
2008-07-29 |
2012-04-06 |
서울대학교병원 |
자연살해세포의 증식방법
|
|
US8481297B2
(en)
|
2009-01-08 |
2013-07-09 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
CN102428173B
(zh)
|
2009-03-26 |
2014-07-30 |
细胞维护北欧制药公司 |
Nk细胞的扩增
|
|
WO2012061814A1
(en)
|
2010-11-05 |
2012-05-10 |
Transgenomic, Inc. |
Pcr primers and methods for rapid and specific genotyping
|
|
US10066207B2
(en)
*
|
2012-04-18 |
2018-09-04 |
Board Of Trustees Of Michigan State University |
Natural killer cells with enhanced immune response
|
|
WO2014037422A1
(en)
*
|
2012-09-04 |
2014-03-13 |
Inven2 As |
Selective and controlled expansion of educated nk cells
|
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
US9902973B2
(en)
|
2013-04-11 |
2018-02-27 |
Caribou Biosciences, Inc. |
Methods of modifying a target nucleic acid with an argonaute
|
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
KR20170032406A
(ko)
|
2014-07-15 |
2017-03-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 조작된 세포
|
|
US10813952B2
(en)
|
2014-11-14 |
2020-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
|
|
US20170137784A1
(en)
|
2015-03-23 |
2017-05-18 |
Cellex Corporation |
NK Cell Culture Container And NK Cell Culture Method
|
|
AU2016274989A1
(en)
|
2015-06-12 |
2017-11-02 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
|
JP7033453B2
(ja)
|
2015-06-30 |
2022-03-10 |
セレクティス |
特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法
|
|
JP6974681B2
(ja)
|
2015-07-29 |
2021-12-01 |
オーエヌケー セラピューティクス リミテッド |
細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株
|
|
CN116376825A
(zh)
|
2015-09-14 |
2023-07-04 |
明尼苏达大学董事会 |
表现出适应性表型的nk细胞以及制备和使用方法
|
|
SG11201803145RA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
KR20250141836A
(ko)
|
2015-11-04 |
2025-09-29 |
페이트 세러퓨틱스, 인코포레이티드 |
만능 세포의 유전자 조작
|
|
SG11201805186VA
(en)
|
2016-01-20 |
2018-07-30 |
Fate Therapeutics Inc |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
JP7653759B2
(ja)
|
2016-01-20 |
2025-03-31 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
JP7086928B2
(ja)
*
|
2016-07-25 |
2022-06-20 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
改変されたナチュラルキラー細胞を生成する方法および使用方法
|
|
CN110546265A
(zh)
|
2017-02-09 |
2019-12-06 |
因达普塔治疗公司 |
工程化自然杀伤(nk)细胞及其组合物和方法
|
|
EP3539552A1
(en)
|
2018-03-16 |
2019-09-18 |
Deutsches Rheuma-Forschungszentrum Berlin |
Activation and expansion of nkg2c+ nk cells
|
|
JP6543375B1
(ja)
|
2018-03-27 |
2019-07-10 |
株式会社ガイアバイオメディシン |
ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
|
|
AU2019271146A1
(en)
|
2018-05-14 |
2020-12-10 |
Indapta Therapeutics, Inc. |
Subsets of human natural killer cells with enhanced antibody-directed immune responses
|
|
EP3884041A2
(en)
|
2018-11-21 |
2021-09-29 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|